1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
51.67 USD   -0.27%
06/24Novavax COVID-19 Vaccine Nuvaxovid Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
AQ
06/24Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid COVID-19 Vaccine for Adolescents Aged 12 Through 17
AQ
06/24Novavax Nuvaxovid COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

B. Riley Lowers Novavax's Price Target to $203 from $250, Notes Relatively Lowered Penetration, Market Share Assumptions in Booster Market; Keeps Buy Rating

04/26/2022 | 08:57am EDT


© MT Newswires 2022
All news about NOVAVAX, INC.
06/24Novavax COVID-19 Vaccine Nuvaxovid Recommended for Expanded Conditional Marketing Autho..
AQ
06/24Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid COVID-19 Vacc..
AQ
06/24Novavax Nuvaxovid COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for U..
AQ
06/24The next COVID booster shots will likely be updated for Omicron
RE
06/24Novavax Wins Taiwanese Regulatory Nod for COVID-19 Vaccine in Adults
MT
06/23Novavax' Nuvaxovid Covid-19 Vaccine Receives Emergency Use Authorization in Taiwan for ..
CI
06/23Novavax's COVID-19 shot authorized in Taiwan for adults
RE
06/23Novavax Gets Taiwan FDA Emergency Use Authorization for Nuvaxovid COVID-19 Vaccine in I..
MT
06/23Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiw..
PR
06/23Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketin..
PR
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 4 274 M - -
Net income 2022 1 935 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 2,20x
Yield 2022 -
Capitalization 4 037 M 4 037 M -
EV / Sales 2022 0,36x
EV / Sales 2023 0,21x
Nbr of Employees 1 541
Free-Float 98,8%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 51,67 $
Average target price 151,86 $
Spread / Average Target 194%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-63.88%4 037
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371